| # | Medikament | Marke | Studientitel | Status | Rating | Vertrauensarzt | Case Manager |
|---|---|---|---|---|---|---|---|
| 1 | Lecanemab | Eisai and Biogen | Lecanemab in Early Alzheimer’s Disease | abgeschlossen 27.07.2025 20:08 |
D | Dr. Heimo Pfeifenberger | Otto Baric |
| 2 | eltrombopag | Novartis | Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia | abgeschlossen 27.07.2025 20:08 |
C | Dr. Heimo Pfeifenberger | Otto Baric |
| 3 | Asfotase alfa | Alexion, AstraZeneca Rare Disease | Effects of asfotase alfa in adults with pediatric-onset hypophosphatasia over 24 months of treatment | abgeschlossen 01.06.2025 17:27 |
C | Dr. Heimo Pfeifenberger | Otto Baric |
| 4 | Sativex Oromucosal Spray | Not specified | Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial | abgeschlossen 27.07.2025 20:08 |
C | Dr. Heimo Pfeifenberger | Otto Baric |
| 5 | Cladribine | Merck Serono | A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis | abgeschlossen 27.07.2025 20:09 |
C | Dr. Heimo Pfeifenberger | Otto Baric |
| 6 | Relugolix | N/A | Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) | abgeschlossen 27.07.2025 20:08 |
C | Dr. Heimo Pfeifenberger | Otto Baric |
| 7 | Difelikefalin | Cara Therapeutics | A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus | abgeschlossen 27.07.2025 20:08 |
C | Dr. Heimo Pfeifenberger | Otto Baric |
| 8 | Semaglutide | Novo Nordisk | A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis | abgeschlossen 27.07.2025 20:09 |
B | Dr. Heimo Pfeifenberger | Otto Baric |
| 9 | Prucalopride | N/A | Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study | abgeschlossen 27.07.2025 20:10 |
B | Dr. Heimo Pfeifenberger | Otto Baric |
| 10 | Prucalopride | N/A | Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study | abgeschlossen 27.07.2025 20:09 |
C | Dr. Heimo Pfeifenberger | Otto Baric |
| 11 | Tofacitinib | N/A | An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch Type Alopecia Areata, Totalis and Universalis | abgeschlossen 27.07.2025 20:09 |
B | Dr. Heimo Pfeifenberger | Otto Baric |
| 12 | Infliximab | N/A | The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies | abgeschlossen 27.07.2025 20:10 |
N/A | Dr. Heimo Pfeifenberger | Otto Baric |
| 13 | Tadalafil | N/A | Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients | abgeschlossen 27.07.2025 20:09 |
C | Dr. Heimo Pfeifenberger | Otto Baric |
| 14 | Vedolizumab | Not specified | Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis | abgeschlossen 27.07.2025 20:09 |
C | Dr. Heimo Pfeifenberger | Otto Baric |